In a series of 55 NSCLC primary tumors with matched cerebral metastases, EGFR was found to be more frequently amplified in the metastatic adenocarcinomas than corresponding primary tumors, with 30 and 10%, respectively (50). This evidence concerns the gene EGFR and non-small cell lung carcinoma.